Syon Capital LLC Lowers Holdings in Fresenius Medical Care AG (NYSE:FMS)

Syon Capital LLC cut its holdings in Fresenius Medical Care AG (NYSE:FMS) by 12.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,530 shares of the company’s stock after selling 2,301 shares during the period. Syon Capital LLC’s holdings in Fresenius Medical Care were worth $323,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Signaturefd LLC raised its holdings in shares of Fresenius Medical Care by 7.3% during the 3rd quarter. Signaturefd LLC now owns 8,601 shares of the company’s stock worth $185,000 after acquiring an additional 584 shares in the last quarter. Morningstar Investment Services LLC increased its position in shares of Fresenius Medical Care by 6.4% during the 3rd quarter. Morningstar Investment Services LLC now owns 10,145 shares of the company’s stock valued at $220,000 after purchasing an additional 612 shares during the last quarter. Hartford Financial Management Inc. increased its position in shares of Fresenius Medical Care by 98.8% during the 4th quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock valued at $35,000 after purchasing an additional 839 shares during the last quarter. Raymond James & Associates increased its position in shares of Fresenius Medical Care by 4.0% during the 4th quarter. Raymond James & Associates now owns 28,960 shares of the company’s stock valued at $603,000 after purchasing an additional 1,125 shares during the last quarter. Finally, Bruce G. Allen Investments LLC bought a new position in shares of Fresenius Medical Care during the 4th quarter valued at approximately $31,000. 8.25% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Down 0.5 %

Fresenius Medical Care stock opened at $20.10 on Friday. The firm has a market cap of $11.80 billion, a price-to-earnings ratio of 21.85, a price-to-earnings-growth ratio of 1.10 and a beta of 1.00. Fresenius Medical Care AG has a 52 week low of $16.37 and a 52 week high of $27.72. The business’s 50-day moving average price is $19.51 and its 200 day moving average price is $19.45. The company has a quick ratio of 1.07, a current ratio of 1.42 and a debt-to-equity ratio of 0.47.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, February 20th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.36 by $0.11. Fresenius Medical Care had a return on equity of 4.99% and a net margin of 2.56%. The company had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.32 billion. As a group, sell-side analysts anticipate that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.

Fresenius Medical Care Cuts Dividend

The firm also recently disclosed an annual dividend, which will be paid on Monday, June 3rd. Shareholders of record on Monday, May 20th will be issued a $0.437 dividend. This represents a yield of 2.35%. The ex-dividend date is Friday, May 17th. Fresenius Medical Care’s payout ratio is currently 45.65%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Morgan Stanley downgraded Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a research report on Monday, January 8th. StockNews.com started coverage on Fresenius Medical Care in a research report on Friday. They issued a “strong-buy” rating on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $32.25.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.